10x Genomics, Inc.TXGNASDAQ
Loading
TXG Revenue Growth (YoY Quarterly)•+0.61%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+0.61%
+2.4pp
+1.88%
+7.6pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+4.51%
+0.6pp
+4.51%
+0.6pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -10.30% | +9.84% | +12.93% | -1.75% | +0.61% |
| Gross Profit Growth | -4.17% | +13.49% | +20.02% | -5.72% | +1.88% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.56% | +2.69% | +3.07% | +3.95% | +4.51% |
| Weighted Average Shares Diluted Growth | +2.56% | +2.69% | +3.70% | +3.95% | +4.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -126.20% | +0.00% | +136.23% | +99.69% | +0.00% |
| Free Cash Flow Growth | -142.42% | +0.00% | +345.83% | +139.56% | +0.00% |
| Receivables Growth | -23.49% | -42.45% | +30.59% | +15.64% | -6.11% |
| Inventory Growth | +12.75% | -10.19% | -21.87% | -34.12% | -32.21% |
| Asset Growth | -4.82% | -2.12% | +5.41% | +9.55% | +13.36% |
| Book Value per Share Growth | -6.56% | -4.24% | +3.61% | +4.49% | +7.30% |
| Debt Growth | -13.38% | -13.13% | -3.06% | +90.31% | +90.93% |
| R&D Expense Growth | +2.61% | -6.40% | -2.69% | -13.57% | -16.42% |
| SG&A Expenses Growth | +8.94% | +4.61% | -10.36% | -7.77% | -18.34% |
1 / 4